Development and validation of a high-performance liquid chromatography-electrospray ionization-MS/MS method for the simultaneous quantitation of levodopa and carbidopa in human plasma

Journal of Mass Spectrometry

Volumn 46, Issue 9, 2011, Pages 943-948

  César, Isabela Costa ^a,b   Byrro, Ricardo Martins Duarte ^a,b   De Santana e Silva Cardoso, Fabiana Fernandes ^a   Mundim, Iram Moreira ^a   De Souza Teixeira, Leonardo ^a   Gomes, Sandro Antônio ^a   Bonfim, Ricardo Rodrigues ^a   Pianetti, Gerson Antônio ^b  

^a Instituto de Ciencias Farmaceuticas   (Brazil)

^b FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

carbidopa HPLC ESI MS MS; levodopa; pharmacokinetics; plasma

Indexed keywords

CARBIDOPA; ELECTROSPRAY SOURCE; HPLC-ESI-MS/MS; HUMAN PLASMAS; INTERNAL STANDARDS; ION TRANSITION; LEVODOPA; METHYLDOPA; MOBILE PHASE; PERCHLORIC ACIDS; PHARMACOKINETIC STUDIES; POSITIVE MODE; PROTEIN PRECIPITATION; SELECTIVE REACTION MONITORING; TABLET FORMULATIONS; TRIPLE-QUADRUPOLE MASS SPECTROMETER;

ACETONITRILE; ELECTROSPRAY IONIZATION; FORMIC ACID; INORGANIC ACIDS; IONIZATION; LIQUID CHROMATOGRAPHY; LIQUIDS; PHARMACOKINETICS; PLASMA (HUMAN); PLASMAS;

DRUG PRODUCTS;

ACETONITRILE; CARBIDOPA; FORMIC ACID; LEVODOPA; METHYLDOPA; PERCHLORIC ACID;

AREA UNDER THE CURVE; ARTICLE; DRUG BLOOD LEVEL; DRUG SENSITIVITY; ELECTROSPRAY MASS SPECTROMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; MAXIMUM PLASMA CONCENTRATION; PARTICLE SIZE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; TABLET FORMULATION;

ADMINISTRATION, ORAL; CARBIDOPA; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG STABILITY; FEMALE; HUMANS; LEVODOPA; MALE; METHYLDOPA; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TABLETS; TANDEM MASS SPECTROMETRY;

EID: 80052790907     PISSN: 10765174     EISSN: 10969888     Source Type: Journal    
DOI: 10.1002/jms.1973     Document Type: Article

References (16)

1. D. Nyholm,. Pharmacokinetic optimisation in the treatment of Parkinson's disease. Clin. Pharmacokinet. 2006, 45, 109.
2. C.W. Olanow, M.B. Stern, K. Sethi,. The scientific and clinical basis for the treatment of Parkinson disease (2009). Neurology. 2009, 72, S1.
3. T. Muller,. Levodopa/carbidopa and entacapone in the treatment of Parkinson's disease: efficacy, safety and patient preference. Patient Prefer. Adherence 2009, 3, 51.
4. K. Eggert, O. Skogar, K. Amar, L. Luotonen, M. Kuoppamaki, M. Leinonen, H. Nissinen, W. Oertel,. Direct switch from levodopa/benserazide or levodopa/carbidopa to levodopa/carbidopa/entacapone in Parkinson's disease patients with wearing-off: efficacy, safety and feasibility-an open-label, 6-week study. J. Neural Transm. 2010, 117, 333.
5. K.C. Yeh, T.F. August, D.F. Bush, K.C. Lasseter, D.G. Musson, S. Schwartz, M.E. Smith, D.C. Titus,. Pharmacokinetics and bioavailability of Sinemet CR: a summary of human studies. Neurology 1989, 39, 25.
6. M. Da Prada, R. Kettler, G. Zurcher, R. Shaffner, W.E. Haefely,. Inhibition of decarboxylase and levels of dopa and 3-Omethyldopa: a comparative study of benserazide versus carbidopa in rodents and of Madopar standard versus Madopar HBS in volunteers. Eur. Neurol. 1987, 27, 9.
7. P.A. LeWitt, M.V. Nelson, R.C. Berchou, M.P. Galloway, N. Kesaree, D. Kareti, P. Schlick,. Controlled-release carbidopa/levodopa (Sinemet 50/200 CR4) : Clinical and pharmacokinetic studies. Neurology 1989, 39, 45.
8. K.A. Sagar, M.R. Smyth,. Bioavailability studies of oral dosage forms containing levodopa and carbidopa using column-switching chromatography followed by electrochemical detection. Analyst 2000, 125, 439.
9. K.A. Sagar, M.R. Smyth,. Simultaneous determination of levodopa, carbidopa and their metabolites in human plasma and urine samples using LC-EC. J. Pharm. Biomed. Anal. 2000, 22, 613.
10. M. Karimi, J.L. Carl, S. Loftin, J.S. Perlmutter,. Modified high-performance liquid chromatography with electrochemical detection method for plasma measurement of levodopa, 3-O-methyldopa, dopamine, carbidopa and 3,4-dihydroxyphenyl acetic acid. J. Chromatogr. B 2006, 836, 120.
11. T. Wikberg,. Simultaneous determination of levodopa, its main metabolites and carbidopa in plasma by liquid chromatography. J. Pharm. Biomed. Anal. 1991, 9, 167.
12. A. Tolokan, I. Klebovich, K. Balogh-Nemes, G. Horvai,. Automated determination of levodopa and carbidopa in plasma by high-performance liquid chromatography-electrochemical detection using an on-line flow injection analysis sample pretreatment unit. J. Chromatogr. B 1997, 698, 201.
13. D.C. Titus, T.F. August, K.C. Yeh, R. Eisenhandler, W.F. Bayne, D.G. Musson,. Simultaneous high-performance liquid chromatographic analysis of carbidopa, levodopa and 3-O-methyldopa in plasma and carbidopa, levodopa and dopamine in urine using electrochemical detection. J. Chromatogr. B 1990, 534, 87.
14. S.F. Li, H.L. Wu, Y.J. Yu, Y.N. Li, J.F. Nie, H.Y. Fu, R.Q. Yu,. Quantitative analysis of levodopa, carbidopa and methyldopa in human plasma samples using HPLC-DAD combined with second-order calibration based on alternating trilinear decomposition algorithm. Talanta 2010, 81, 805.
15. W. Jiang, L. Lv, S. Zhou, X. Huang, X. Shi, C. Lv, L. Wu, C. Xu,. Simultaneous determination of L-dopa and its prodrug (S)-4-(2-acetamido-3- ethoxy-3-oxopropyl)-1,2-phenylene diacetate in rat plasma by high-performance liquid chromatography-tandem mass spectrometry and its application in a pharmacokinetic study. J. Pharm. Biomed. Anal. 2010, 53, 751.
16. Food and Drug Administration. FDA Guidance for Industry: Bioanalytical Method Validation. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research: Rockville, 2001.